Favorite  |  Set Home
Products > JAK/STAT > JAK > Oclacitinib
Product name : Oclacitinib
Item : CR1869
Price : 200mg, $950;500mg, $1695; 1g, $2490; 2g, $3590
contact : Send inquiry to: info@acesobio.com
CAS : 1208319-26-9
Molecular Weight : 337.44
Formula : C₁₅H₂₃N₅O₂S
Storage : at -20°C
Additional information : We offer significant discount for bulky quantity order
 Enlarge Image                   Back
←[Previous Product]              [Next Product]→


Details:
 Chemical Information
M.Wt 337.44 Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Formula C15H23N5O2S
CAS No 1208319-26-9
Solubility

DMSO



Biological Activity of Oclacitinib

 

Oclacitinib(PF03394197) is a potent and selective JAKs inhibitor with IC50 of 10-99 nM; not inhibit a panel of 38 non-JAK kinases (IC50 's > 1000 nM).
IC50 value: 10 nM (JAK1) [1]
Target: JAKs
in vitro: Oclacitinib inhibited the function of JAK1-dependent cytokines involved in allergy and inflammation (IL-2, IL-4, IL-6, and IL-13) as well as pruritus (IL-31) at IC50 's ranging from 36 to 249 nm. Oclacitinib had minimal effects on cytokines that did not activate the JAK1 enzyme in cells (erythropoietin, granulocyte/macrophage colony-stimulating factor, IL-12, IL-23; IC50 's > 1000 nm) [1].
in vivo: Dogs were randomized to receive either oclacitinib (0.4-0.6 mg/kg twice daily for 14 days and then once daily for up to 112 days) or an excipient-matched placebo [2].Dogs were randomized to either oclacitinib at 0.4-0.6 mg/kg orally twice daily or an excipient-matched placebo. An enhanced 10 cm visual analog scale (VAS) was used by the owners to assess the severity of pruritus from day 0 to 7 and by veterinarians to assess the severity of dermatitis on days 0 and 7. Dogs could remain on the study for 28 days [3].
 

 

[1]. Gonzales AJ, et al. Oclacitinib (APOQUEL) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J Vet Pharmacol Ther. 2014 Aug;37(4):317-24.

[2]. Cosgrove SB, et al. A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel) in client-owned dogs with atopic dermatitis. Vet Dermatol. 2013 Dec;24(6):587-97, e141-2.

[3]. Cosgrove SB, et al. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Vet Dermatol. 2013 Oct;24(5):479-e114.


Related Products :
AZ 960
AZ 960
Price: 200mg, $750;500mg, $1190; 1g $1890; 2g, $2995
LY 2784544
LY 2784544
Price: 200mg, $750;500mg, $1190; 1g $1890; 2g, $2995
NVP-BSK805
NVP-BSK805
Price: 200mg, $950;500mg, $1595; 1g $2390; 2g, $3590
CYT 387 (CYT11387)
CYT 387 (CYT11387)
Price: 200mg, $659;500mg, $1050; 1g $1595; 2g, $2355
WP 1066
WP 1066
Price: 200mg, $659;500mg, $1050; 1g $1595; 2g, $2355
TG 101209
TG 101209
Price: 10mg, $275; 50mg, $765; 100mg, $1295; 200mg, $2195
Upadacitinib (Synonyms: ABT-494)
Upadacitinib (Synonyms: ABT-494)
Price: 200mg, $1750;500mg, $2890; 1g, $3950;
TG 101348
TG 101348
Price: 200mg, $449;500mg, $850; 1g $1195; 2g, $1795